DOCSLIB.ORG

The Claimed Intermediate Online Database | Drug Names to Search: Control F (PC) Command F (Mac) Open & Search in Ibooks App (Ipad)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Claimed Intermediate Online Database | Drug Names to Search: Control F (PC) Command F (Mac) Open & Search in Ibooks App (Ipad) The Claimed Intermediate Online Database | Drug Names www.tcipatent.com To search: Control F (PC) Command F (Mac) Open & search in iBooks app (iPad) Drug Name Abiraterone Acetaminophen Adefovir Dipivoxil Agomelatine Albendazole Alendronic acid Alfentanil Aliskiren Allopurinol Almorexant Almotriptan Alogliptin Alosetron Alprostadil Alvimopan www.tcipatent.com Ambrisentan Aminaphtone Amisulpride Amlodipine Amorolfine Amphetamine Amprenavir Amrubicin Amylmetacresol Anagrelide Anastrozole www.tcipatent.com Apixaban Aprepitant Arformoterol Argatroban Aripiprazole Armodafinil Artemether Artemisinin Asenapine Aspirin Atazanavir www.tcipatent.com Atomoxetine Atorvastatin Atorvastatin ( Rosuvastatin Ezetimibe Linezolid ) Atovaquone Azacitidine Azilsartan Azilsartan medoxomil Azithromycin Baclofen Bazedoxifene Bendamustine www.tcipatent.com Benidipine Betaxolol Bexarotene Biapenem Bicalutamide Bimatoprost Bimatoprost ( Latanoprost Travoprost ) Bisoprolol Bivalirudin Boceprevir Bortezomib www.tcipatent.com Bosentan Brinzolamide Bromfenac Buclizine Buprenorphine Bupropion Cabazitaxel Cabazitaxel ( Docetaxel Paclitaxel ) Candesartan cilexetil Capecitabine Carbabenzpyride Caspofungin Cefamandole www.tcipatent.com Cefdinir Cefditoren pivoxil Cefepime Cefixime Cefoperazone Cefotaxime Cefozopran Cefpodoxime Cefpodoxime proxetil Ceftaroline fosamil Ceftobiprole www.tcipatent.com Ceftobiprole medocaril Ceftriaxone Celecoxib Cetirizine Cevimeline Chloroquine Chlorothiazide Cidofovir Cilastatin Cilazapril Cinacalcet www.tcipatent.com Ciprofloxacin Cisatracurium Besylate Citalopram Cladribine Clarithromycin Clevidipine Clevidipine ( Nifedipine Nimodipine Nisoldipine Nitrendipine ) Clocortolone Clofarabine Clopidogrel Cloxacillin Cyclobenzaprine Dabigatran etexilate Dapoxetine Dapsone www.tcipatent.com Darifenacin Darunavir Darunavir ( Amprenavir Fosamprenavir ) Dasatinib Decitabine Deferasirox Degarelix Desflurane Desloratidine Desogestrel Desoximetasone www.tcipatent.com Desvenlafaxine Dexlansoprazole Dexmedetomidine Dextroamphetamine Diclofenac Dicloxacillin Dienogest Diflucortolone Dihydrocodeine Dihydroetorphine Dihydromorphine www.tcipatent.com Dimebon Diosmin Dipyridamole Docetaxel Docetaxel ( Paclitaxel ) Donepezil Doripenem Dorzolamide Doxapram Doxazosin Doxercalciferol www.tcipatent.com Dronabinol Dronedarone Drospirenone Droxidopa Duloxetine Duloxetine ( Atomoxetine Fluoxetine Nisoxetine Tomoxetine ) Dutasteride Ebastine Efavirenz Eletriptan Eltrombopag www.tcipatent.com Emtricitabine Enoxaparin Entecavir Epirubicin Eplerenone Eprosartan Eribulin Erlotinib Ertapenem Erythromycin Escitalopram www.tcipatent.com Eslicarbazepine acetate Esomeprazole Estradiol Estradiol valerate Eszopiclone Ethambutol Etonogestrel Etoricoxib Etravirine Everolimus Exemestane www.tcipatent.com Ezetimibe Fampridine Febuxostat Felbamate Felodipine Felodipine ( Amlodipine Clevidipine Isradipine Nifedipine Nimodipine Nisoldipine ) Ferric carboxymaltose Fesoterodine Fesoterodine ( Tolterodine ) Fexofenadine Fingolimod Flucloxacillin www.tcipatent.com Fluconazole Fludarabine Fludeoxyglucose (18F) Fluorometholone Fluoxetine Flupirtine Flurbiprofen Fluticasone furoate Fluticasone propionate Fluvastatin Fondaparinux www.tcipatent.com Fondaparinux sodium Fosamprenavir Fosaprepitant Fosinopril Frovatriptan Fulvestrant Gabapentin Gabapentin enacarbil Gadobenic acid Gadobutrol Gadoxetic acid www.tcipatent.com Galantamine ( Morphine Codeine ) Ganciclovir Gefitinib Gemcitabine Gestodene Glatiramer acetate Gliclazide Glycopyrronium bromide Glycopyrronium chloride Hydrocodone Hydromorphone www.tcipatent.com Hydromorphone ( Hydrocodone ) Hydroxychloroquine Hydroxyzine Ibandronic acid Ibuprofen Idarubicin Iloperidone Imatinib Imipenem Indeloxazine Ingenol mebutate www.tcipatent.com Iodixanol Ioflupane (123I) Iohexol Iomeprol Iopamidol Iopamidol ( Iomeprol ) Ioversol Irbesartan Irinotecan Isoflurane Itraconazole www.tcipatent.com Ivabradine Ixabepilone Ketoconazole Ketoprofen Lacosamide Lamivudine Lansoprazole Lapatinib Lasofoxifene Latanoprost Latrepirdine www.tcipatent.com Lenalidomide Lercanidipine Letrozole Levetiracetam Levocarnitine Levocetirizine Levocetirizine ( Cetirizine Meclizine Chlorcyclizine Clocinizine Buclizine ) Levofloxacin Levonorgestrel Levosimendan Levothyroxine Linagliptin Linezolid Lisdexamfetamine Lisinopril Lofexidine Lopinavir Lorcaserin www.tcipatent.com Losartan Lovastatin Lubiprostone Lurasidone Manidipine Maxacalcitol Meclizine Medetomidine Mefloquine Melphalan Memantine www.tcipatent.com Menadione Mequitazine Meropenem Meropenem ( Ertapenem Doripenem Biapenem ) Mesalazine Metaxalone Metformin Methamphetamine Methotrexate ( Permetrexed Pralatrexate Raltitrexed ) Methylnaltrexone bromide Methylphenidate www.tcipatent.com Micafungin Milnacipran Minodronic acid Mirtazapine Mitiglinide Mivacurium chloride Montelukast Moxifloxacin Moxonidine Mycophenolate mofetil Nabilone www.tcipatent.com Nalbuphine Nalbuphone ( Naloxone ) Nalmefene Naloxone Naltrexone Naltrexone ( Naloxone ) Naproxen Naratriptan Nateglinide Nebivolol Neostigmine www.tcipatent.com Nepafenac Neridronic acid Nicardipine Nicorandil Nilotinib Nisoldipine Norepinephrine Olanzapine Olmesartan Medoxomil Olopatadine Olopatidine Omeprazole Omeprazole ( Pantoprazole Lansoprazole Rabeprazole Modafinil ) www.tcipatent.com Orlistat Oseltamivir Oxacillin Oxaliplatin Oxcarbazepine Oxiracetam Oxycodone Oxymorphone Paclitaxel Paliperidone Palonosetron www.tcipatent.com Pamidronic acid Panipenem Pantoprazole Paricalcitol Pazopanib Pemetrexed Peramivir Perampanel Perindopril Phenobarbital Phenylephrine www.tcipatent.com Pimecrolimus Pimobendan Piperaquine Pirfenidone Piritramide Pitavastatin Pitavastatin ( Fluvastatin Pravastatin Atorvastatin Rosuvastatin ) Pitavastatin ( Fluvastatin Rosuvastatin ) Polymyxin B Posaconazole Pralatrexate Pramipexole Pramlintide Pranlukast Prasugrel www.tcipatent.com Praziquantel Pregabalin Propiverine Propofol Prulifloxacin Quetiapine Rabeprazole Racecadotril Raloxifene Raltegravir Ramelteon www.tcipatent.com Ramipril Ranitidine Ranolazine Rasagiline Reboxetine Regadenoson Remifentanil Repaglinide Retapamulin Retigabine Rifaximin www.tcipatent.com Rilpivirine Riluzole Risedronic acid Risperidone Ritodrine Rivaroxaban Rivastigmine Rizatriptan Rocuronium bromide Roflumilast Ropinirole www.tcipatent.com Ropivacaine Rosuvastatin Rosuvastatin ( Fluvastatin Pitavastatin ) Rotigotine Rufinamide Salmeterol Sapropterin Saquinavir Saxagliptin Sertraline Sevoflurane www.tcipatent.com Silodosin Simvastatin Sitagliptin Sodium oxybate Solifenacin Sorafenib Strontium ranelate Sufentanil Sunitinib Tadalafil Tamsulosin www.tcipatent.com Tapentadol Taurolidine Tebipenem pivoxil Telaprevir Telavancin Telmisartan Temazepam Temozolomide Temsirolimus Tenofovir Tenofovir disoproxil www.tcipatent.com Tetrabenazine Thalidomide Tianeptine Ticagrelor Ticarcillin Tigecycline Tiopronin Tiotropium bromide Tofacitinib Tolterodine Topiramate Toremifene www.tcipatent.com Trabectedin Tramadol Trandolapril Travoprost Treprostinil Triclabendazole Ulipristal Valganciclovir Valsartan Vardenafil Varenicline www.tcipatent.com Venlafaxine Vercuronium bromide Vernakalant Vildagliptin Viloxazine Vinpocetine Voglibose Voriconazole Vorinostat Zanamivir Zidovudine www.tcipatent.com Zileuton Ziprasidone Zofenopril Zoledronic acid Zolmitriptan Zolpidem www.tcipatent.com.
Load more

Recommended publications
  • Download Product Catalog
    Total Quality Medications Product Portfolio Rx Product name Dosage form Generic name Pack size Indications A- Alimentary tract and metabolism A02B – Proton pump inhibitor Omecarbex 20 mg H.G Cap Omeprazole +Na 20 Caps Acid reflux and Ulcers Omecarbex 40 mg H.G Cap Carbonate 20 Caps Acid reflux and Ulcers A06A - Laxatives Amiprostone 8 mcg S.G Cap Lubiprostone 20 Capsules Laxative Amiprostone 24 mcg S.G Cap Lubiprostone 10 Capsules Laxative A07A- Intestinal Anti-infective Anti-diarrheal Gastrobiotic 200 mg Tablets Rifiximin 20 Tablets Antidiarrheal Gastrobiotic 550 mg Tablets Rifiximin 30 Tablets Antidiarrheal Nitazode 100 mg/5 ml Suspension Nitazoxanide Bottle 60 ml Antiprotozoal A10B- Oral Anti -diabetics A10-BD - Oral hypoglycemic associations Glimepiride+ Improve glycemic control for type 2 Glimepiride plus 4/30 Tablets 30 Tablets Pioglitazone Hcl diabetes Glimepiride+ Improve glycemic control for type 2 Glimepiride plus 2/30 Tablets 30 Tablets Pioglitazone Hcl diabetes Metformin Hcl + Improve glycemic control for type 2 Bioglitaplus 15/500 Tablets 20 Tablets Pioglitazone Hcl diabetes Metformin Hcl + Improve glycemic control for type 2 Bioglitaplus 15/850 Tablets 20 Tablets Pioglitazone Hcl diabetes A10BX - Other anti diabetics Control the elevation of blood sugar Megy One 10 mg Tablets Mitiglinide 20 Tablets after eating B- Blood and blood forming organs B01A - Anti-thrombotic agents Andorivaban 10 mg F.C Tablets Rivaroxaban 20 Tablets Anticoagulants Andorivaban 15 mg F.C Tablets Rivaroxaban 20 Tablets Anticoagulants Andorivaban 20
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Summary of Product Characteristics
    SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT *IPERTEN/ARTEDIL/MANYPER 10mg tablets IPERTEN/ARTEDIL/MANYPER 20mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION IPERTEN/ARTEDIL/MANYPER 10 mg tablets Each tablet contains: Manidipine hydrochloride 10mg Excipient with known effect: 119,61 mg lactose monohydrate/tablet IPERTEN/ARTEDIL/MANYPER 20 mg tablets Each tablet contains: Manidipine hydrochloride 20mg Excipient with known effect: 131,80 mg lactose monohydrate/tablet For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet IPERTEN/ARTEDIL/MANYPER 10mg: pale yellow, round, scored tablet; IPERTEN/ARTEDIL/MANYPER 20mg: yellow-orange, oblong, scored tablet. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Mild to moderate essential hypertension 4.2 Posology and method of administration The recommended starting dose is 10 mg once a day. Should the antihypertensive effect be still insufficient after 2-4 weeks of treatment, it is advisable to increase the dosage to the usual maintenance dose of 20 mg once a day. Elderly In view of the slowing down of metabolism in the elderly, the recommended dose is 10mg once daily. This dosage is sufficient in most elderly patients; the risk/benefit of any dose increase should be considered with caution on an individual basis. Renal impairment In patients with mild to moderate renal dysfunction care should be taken when increasing the dosage from 10 to 20mg once a day. Hepatic impairment Due to the extensive hepatic metabolisation of manidipine, patients with mild hepatic dysfunction should not exceed 10mg once a day (see also Section 4.3 Contraindications). Tablet must be swallowed in the morning after breakfast, without chewing it, with a few liquid.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • The Repurposing Drugs in Oncology Database
    ReDO_DB: the repurposing drugs in oncology database Pan Pantziarka1,2, Ciska Verbaanderd1,3, Vidula Sukhatme4, Rica Capistrano I1, Sergio Crispino1, Bishal Gyawali1,5, Ilse Rooman1,6, An MT Van Nuffel1, Lydie Meheus1, Vikas P Sukhatme4,7 and Gauthier Bouche1 1The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium 2The George Pantziarka TP53 Trust, London, UK 3Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium 4GlobalCures Inc., Newton, MA 02459 USA 5Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 USA 6Oncology Research Centre, Vrije Universiteit Brussel, Brussels, Belgium 7Emory University School of Medicine, Atlanta, GA 30322 USA Correspondence to: Pan Pantziarka. Email: [email protected] Abstract Repurposing is a drug development strategy that seeks to use existing medications for new indications. In oncology, there is an increased level of activity looking at the use of non-cancer drugs as possible cancer treatments. The Repurposing Drugs in Oncology (ReDO) project has used a literature-based approach to identify licensed non-cancer drugs with published evidence of anticancer activity. Data from 268 drugs have been included in a database (ReDO_DB) developed by the ReDO project. Summary results are outlined and an assessment Research of clinical trial activity also described. The database has been made available as an online open-access resource (http://www.redo-project. org/db/). Keywords: drug repurposing, repositioning, ReDO project, cancer drugs, online database Published: 06/12/2018 Received: 27/09/2018 ecancer 2018, 12:886 https://doi.org/10.3332/ecancer.2018.886 Copyright: © the authors; licensee ecancermedicalscience.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Sulfonylurea Stimulation of Insulin Secretion Peter Proks,1 Frank Reimann,2 Nick Green,1 Fiona Gribble,2 and Frances Ashcroft1
    Sulfonylurea Stimulation of Insulin Secretion Peter Proks,1 Frank Reimann,2 Nick Green,1 Fiona Gribble,2 and Frances Ashcroft1 Sulfonylureas are widely used to treat type 2 diabetes smooth, and skeletal muscle, and some brain neurones. In because they stimulate insulin secretion from pancre- all these tissues, opening of KATP channels in response to atic ␤-cells. They primarily act by binding to the SUR metabolic stress leads to inhibition of electrical activity. subunit of the ATP-sensitive potassium (KATP) channel Thus they are involved in the response to both cardiac and and inducing channel closure. However, the channel is cerebral ischemia (2). They are also important in neuronal still able to open to a limited extent when the drug is regulation of glucose homeostasis (3), seizure protection bound, so that high-affinity sulfonylurea inhibition is not complete, even at saturating drug concentrations. (4), and the control of vascular smooth muscle tone (and, thereby, blood pressure) (5). KATP channels are also found in cardiac, skeletal, and smooth muscle, but in these tissues are composed of The KATP channel is a hetero-octameric complex of two different SUR subunits that confer different drug different types of protein subunits: an inwardly rectifying sensitivities. Thus tolbutamide and gliclazide block Kϩ channel, Kir6.x, and a sulfonylurea receptor, SUR (6,7). ␤ ϩ channels containing SUR1 ( -cell type), but not SUR2 Kir6.x belongs to the family of inwardly rectifying K (cardiac, smooth muscle types), whereas glibenclamide, (Kir) channels and assembles as a tetramer to form the glimepiride, repaglinide, and meglitinide block both types of channels.
    [Show full text]
  • Guidelines of Hypertension – 2020 Barroso Et Al
    Brazilian Guidelines of Hypertension – 2020 Barroso et al. Guidelines Brazilian Guidelines of Hypertension – 2020 Development: Department of Hypertension of the Brazilian Society of Cardiology (DHA-SBC), Brazilian Society of Hypertension (SBH), Brazilian Society of Nephrology (SBN) Norms and Guidelines Council (2020-2021): Brivaldo Markman Filho, Antonio Carlos Sobral Sousa, Aurora Felice Castro Issa, Bruno Ramos Nascimento, Harry Correa Filho, Marcelo Luiz Campos Vieira Norms and Guidelines Coordinator (2020-2021): Brivaldo Markman Filho General Coordinator: Weimar Kunz Sebba Barroso Coordination Work Group: Weimar Kunz Sebba Barroso, Cibele Saad Rodrigues, Luiz Aparecido Bortolotto, Marco Antônio Mota-Gomes Guideline Authors: Weimar Kunz Sebba Barroso,1,2 Cibele Isaac Saad Rodrigues,3 Luiz Aparecido Bortolotto,4 Marco Antônio Mota-Gomes,5 Andréa Araujo Brandão,6 Audes Diógenes de Magalhães Feitosa,7,8 Carlos Alberto Machado,9 Carlos Eduardo Poli-de-Figueiredo,10 Celso Amodeo,11 Décio Mion Júnior,12 Eduardo Costa Duarte Barbosa,13 Fernando Nobre,14,15 Isabel Cristina Britto Guimarães,16 José Fernando Vilela- Martin,17 Juan Carlos Yugar-Toledo,17 Maria Eliane Campos Magalhães,18 Mário Fritsch Toros Neves,6 Paulo César Brandão Veiga Jardim,2,19 Roberto Dischinger Miranda,11 Rui Manuel dos Santos Póvoa,11 Sandra C. Fuchs,20 Alexandre Alessi,21 Alexandre Jorge Gomes de Lucena,22 Alvaro Avezum,23 Ana Luiza Lima Sousa,1,2 Andrea Pio-Abreu,24 Andrei Carvalho Sposito,25 Angela Maria Geraldo Pierin,24 Annelise Machado Gomes de Paiva,5 Antonio
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • 174-Atypical Antipsychotics and Sleepwalkingsleep-Related Eating
    Atypical antipsychotics and sleepwalking/sleep-related eating disorder CONFIDENTIAL Medicines Adverse Reactions Committee Meeting date 3 July 2018 Agenda item 3.2.2 Title Atypical antipsychotics and sleepwalking/sleep-related eating disorder Medsafe For advice Submitted by Paper type Pharmacovigilance Team Active constituent Medicine Sponsors Amisulpride Solian Sanofi-Aventis Sulprix Mylan Aripiprazole Abilify Pharmacy Retailing Aripiprazole Sandoz Novartis Clozapine Clopine Douglas Pharmaceuticals Clozaril Mylan Olanzapine Olanzapine DRLA Dr Reddy’s Zypine Mylan Zyprexa Eli Lilly Paliperidone Invega Janssen-Cilag Quetiapine Auro-Quetiapine Aurobindo Pharma DP-Quetiapine Douglas Pharmaceuticals Quetapel Mylan Quetiapine DRLA Dr Reddy’s Seroquel AstraZeneca Risperidone Ridal Douglas Pharmaceuticals Risperdal Janssen-Cilag Risperidone DRLA Dr Reddy’s Risperidone (Teva) Teva Pharma Risperon Mylan Ziprasidone Zeldox Pfizer Zusdone Douglas Pharmaceuticals Funding All of the above active constituents have a funded brand with the exception of paliperidone. The special authority criteria for aripiprazole was removed on 1 June 2018. Previous MARC Atypical antipsychotics and sleepwalking/sleep-related eating disorder has meetings not been discussed previously. International action Health Canada − In September 2017, Health Canada issued a safety review on the potential risk of sleepwalking and sleep-related eating disorder associated with atypical antipsychotics. Based on this review, Health Canada has recommended updating the product safety information
    [Show full text]
  • Pharmacokinetic and Pharmacodynamic Modeling of Oral
    Liu et al. BMC Pharmacology and Toxicology (2017) 18:54 DOI 10.1186/s40360-017-0161-6 RESEARCH ARTICLE Open Access Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers Shijia Liu1, Peidong Chen2, Yang Zhao3, Guoliang Dai1, Bingting Sun2, Yao Wang1, Anwei Ding2 and Wenzheng Ju1* Abstract Background: Mitiglinide is a widely used agent for diabetic treatment. We established a pharmacokinetic- pharmacodynamic (PK-PD) model to illustrate the relationship between mitiglinide plasma concentration and its glucose lowering effects in healthy volunteers. Methods: The volunteers participated in the test after the administration of a single dose of 10 mg mitiglinide. The drug concentration in Plasma and the values of glucose levels were determined by LC-MS/MS assay and hexokinase method. A PK-PD model was established with a series of equations to describe the relationship between plasma medicine and glucose, and the equations were solved numerically and fitted to the data with the Phoenix NLME software. Results: The results of the two-compartment model analysis were based on the maximum likelihood criterion and visual inspection of the fittings. The terminal elimination half-life (t1/2) was 1.69 ± 0.16 h and the CL/F was 7.80 ± 1.84 L/h. The plasma glucose levels began to decline by 0.2 h, and hit its bottom decreasing values of 2.6 mg/L at 0.5 h after administration. The calculated parameter and fitting curve indicated that the model established in our experiment fitted well. Conclusions: A PK/PD model illustrates that the relationship between mitiglinide concentration in plasma and glucose lowering effect in healthy volunteers was established.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]